European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021
Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fuentes Ana, Serrano-Conde Esther, Roldán Carolina, Benito-Ruesca Rafael, Mejías Gregoria, Sampedro Antonio, March-Roselló Gabriel, Fernández-Natal Isabel, Esperalba Juliana, Rodríguez Mario José, Martínez de Aguirre Paula, Salas Carlos, Roc María Lourdes, Soria Luis Miguel, Parra-Grande Mónica, Montero María Dolores, Fernández-Roblas Ricardo, Franco-Álvarez de Luna Francisco, Lozano Carmen, García Federico
Аннотация
AIM: To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic.
METHODS: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used.
RESULTS: Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively.
CONCLUSION: The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
METHODS: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used.
RESULTS: Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively.
CONCLUSION: The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
Предметные рубрики MeSH
AdolescentAdultAge FactorsAgedAged, 80 and overAntibodies, ViralAntibody FormationCOVID-19COVID-19 Serological TestingCoronavirus Nucleocapsid ProteinsEnzyme-Linked Immunosorbent AssayFemaleHospitalizationHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MMaleMiddle AgedPhosphoproteinsSensitivity and SpecificitySex FactorsSpainSpike Glycoprotein, CoronavirusYoung Adult